348 results on '"Hoi, Alberta"'
Search Results
2. Smith-specific regulatory T cells halt the progression of lupus nephritis
3. Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
4. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
5. OMERACT systemic lupus erythematosus domain survey
6. Systemic lupus erythematosus
7. The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
8. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set
9. Autoimmune rheumatic disease in Australian Aboriginal and Torres Strait Islander Peoples: What do we know?
10. Management of ankylosing spondylitis
11. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study
12. CSL362 potently and specifically depletes pDCs in vitro and ablates SLE-immune complex-induced IFN responses
13. Type I Interferons and the Perpetuation of a Loss of Tolerance
14. Intracellular Targets in SLE
15. The Concept of Co-Stimulatory Blockade in SLEplease remove Aff4
16. Cytokines: Their Role in Amplifying SLE Pathogenesis
17. Advances in Translational Science to Identify New Therapies for Systemic Lupus Erythematosus
18. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study
19. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study
20. Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
21. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
22. Association of clinic setting with quality indicator performance in systemic lupus erythematosus: a cross-sectional study
23. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
24. Comparison Of Attainment And Protective Effects Of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established SLE.
25. P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: are we doing it enough?
26. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study
27. Global epidemiology of systemic lupus erythematosus
28. Enrolment of the first paediatric cohort into the Australian lupus registry and biobank: A single-centre experience.
29. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study
30. Disease course following High Disease Activity Status revealed patterns in SLE
31. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study
32. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
33. LSO-036 Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific lupus collaboration cohort (APLC-CASTLE)
34. LSO-031 Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort
35. LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)
36. LO-004 Frequency and determinants of flare and persistently active disease in a large multinational prospective lupus cohort
37. LP-067 Analysis of hospital length of stay in systemic lupus erythematosus patients hospitalised with infection
38. LSO-080 Machine-learning approach on lupus low disease activity prediction
39. LSO-087 Sub-optimal use of anti-malarial therapy for SLE in the Asia Pacific region; observations from the Asia Pacific lupus cohort
40. Publisher Correction: Global epidemiology of systemic lupus erythematosus
41. Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus
42. Systemic lupus erythematosus: Unmasking the masquerader.
43. The use of belimumab in three cases of refractory lupus nephritis.
44. Primary aldosteronism: an unsuspected culprit of hypertension in systemic lupus erythematosus?
45. Smith-specific regulatory T cells halt the progression of lupus nephritis
46. Clinical associations of cognitive dysfunction in systemic lupus erythematosus
47. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
48. Predictors of infection requiring hospitalization in patients with systemic lupus erythematosus: a time-to-event analysis
49. Cutaneous clues to clinch a diagnosis amidst pandemic
50. Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.